ZA201309400B - Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms - Google Patents

Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms

Info

Publication number
ZA201309400B
ZA201309400B ZA2013/09400A ZA201309400A ZA201309400B ZA 201309400 B ZA201309400 B ZA 201309400B ZA 2013/09400 A ZA2013/09400 A ZA 2013/09400A ZA 201309400 A ZA201309400 A ZA 201309400A ZA 201309400 B ZA201309400 B ZA 201309400B
Authority
ZA
South Africa
Prior art keywords
treatment
cell malignancies
maytansinoid immunoconjugate
immunoconjugate antibody
symptoms
Prior art date
Application number
ZA2013/09400A
Other languages
English (en)
Inventor
Rodica Morariu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201309400(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA201309400B publication Critical patent/ZA201309400B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2013/09400A 2011-05-17 2013-12-12 Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms ZA201309400B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290232A EP2524929A1 (en) 2011-05-17 2011-05-17 Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PCT/EP2012/059141 WO2012156455A1 (en) 2011-05-17 2012-05-16 Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms

Publications (1)

Publication Number Publication Date
ZA201309400B true ZA201309400B (en) 2015-04-29

Family

ID=46085972

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/09400A ZA201309400B (en) 2011-05-17 2013-12-12 Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms

Country Status (30)

Country Link
US (2) US9555126B2 (cg-RX-API-DMAC7.html)
EP (2) EP2524929A1 (cg-RX-API-DMAC7.html)
JP (4) JP6050328B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140043388A (cg-RX-API-DMAC7.html)
CN (2) CN103547596A (cg-RX-API-DMAC7.html)
AR (1) AR086412A1 (cg-RX-API-DMAC7.html)
AU (3) AU2012258254B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013029330A8 (cg-RX-API-DMAC7.html)
CA (1) CA2835738A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013003272A1 (cg-RX-API-DMAC7.html)
CO (1) CO6821893A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130593A (cg-RX-API-DMAC7.html)
DO (1) DOP2013000260A (cg-RX-API-DMAC7.html)
EA (1) EA028574B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13013084A (cg-RX-API-DMAC7.html)
GT (1) GT201300276A (cg-RX-API-DMAC7.html)
IL (3) IL229380B (cg-RX-API-DMAC7.html)
MA (1) MA35180B1 (cg-RX-API-DMAC7.html)
MX (1) MX347019B (cg-RX-API-DMAC7.html)
MY (1) MY163736A (cg-RX-API-DMAC7.html)
NI (1) NI201300119A (cg-RX-API-DMAC7.html)
PE (1) PE20141018A1 (cg-RX-API-DMAC7.html)
PH (2) PH12013502305A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201609729VA (cg-RX-API-DMAC7.html)
TN (1) TN2013000468A1 (cg-RX-API-DMAC7.html)
TW (3) TW201726167A (cg-RX-API-DMAC7.html)
UA (1) UA114401C2 (cg-RX-API-DMAC7.html)
UY (1) UY34077A (cg-RX-API-DMAC7.html)
WO (1) WO2012156455A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201309400B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US9637547B2 (en) 2013-08-30 2017-05-02 Immunogen, Inc. Monoclonal antibodies for detection of folate receptor 1
CN105837689B (zh) * 2015-01-13 2020-06-19 博生吉安科细胞技术有限公司 抗cd19单克隆抗体及其制备方法
WO2016180941A1 (en) * 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
CA2986175A1 (en) 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
DK3380525T3 (da) 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
MA45124B1 (fr) 2016-05-30 2021-05-31 Morphosys Ag Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
CN115998859A (zh) 2016-06-27 2023-04-25 莫佛塞斯公司 抗-cd19抗体制剂
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
MX2019012462A (es) * 2017-04-20 2020-07-27 Adc Therapeutics Sa Terapia combinada.
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
AU2018336520B2 (en) 2017-09-21 2025-03-27 WuXi Biologics Ireland Limited Novel anti-CD19 antibodies
MA50185A (fr) 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nouveaux complexes polypeptidiques cd3/cd19 bispécifiques
CN111587125A (zh) 2018-01-12 2020-08-25 伊缪诺金公司 抗体药物缀合、纯化和调配的方法
EP3958977B1 (en) 2019-04-26 2023-09-13 ImmunoGen, Inc. Camptothecin derivatives
MX2021013101A (es) 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
IL317199A (en) 2019-10-31 2025-01-01 Morphosys Ag Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
CA3153636A1 (en) * 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
CN111303286B (zh) * 2019-12-05 2022-05-20 常州费洛斯药业科技有限公司 一种anti-CD19的全人源抗体或抗体片段及其嵌合抗原受体和应用
CN115956088A (zh) 2020-06-22 2023-04-11 莫佛塞斯公司 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法
IL301865A (en) 2020-10-06 2023-06-01 Xencor Inc Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
US20220184208A1 (en) 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
JP2025528837A (ja) 2022-08-17 2025-09-02 インサイト・コーポレイション 抗ｃｄ１９抗体及びｅｚｈ２モジュレーターを含む治療
WO2025087382A1 (zh) * 2023-10-26 2025-05-01 上海先博生物科技有限公司 靶向cd19的嵌合抗原受体的治疗用途
WO2025157132A1 (en) 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CR20170291A (es) 2003-05-20 2017-07-27 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
CA2662340C (en) * 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP3360879A1 (en) * 2009-02-05 2018-08-15 ImmunoGen, Inc. Benzodiazepine derivatives as cytotoxic agents
JP2012526079A (ja) * 2009-05-06 2012-10-25 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８を標的とする免疫複合体の使用
RU2012120691A (ru) * 2009-10-21 2013-11-27 Иммьюноджен, Инк. Новый режим дозирования и способ лечения
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab

Also Published As

Publication number Publication date
AR086412A1 (es) 2013-12-11
MA35180B1 (fr) 2014-06-02
WO2012156455A1 (en) 2012-11-22
SG10201609729VA (en) 2016-12-29
US20170196988A1 (en) 2017-07-13
IL229380B (en) 2018-02-28
EA201391714A1 (ru) 2014-03-31
IL229380A0 (en) 2014-01-30
NZ618012A (en) 2016-03-31
CA2835738A1 (en) 2012-11-22
JP2019142961A (ja) 2019-08-29
JP2017081926A (ja) 2017-05-18
TWI601537B (zh) 2017-10-11
ECSP13013084A (es) 2014-01-31
NI201300119A (es) 2014-02-28
CO6821893A2 (es) 2013-12-31
CL2013003272A1 (es) 2014-08-01
TW201249460A (en) 2012-12-16
MX347019B (es) 2017-04-07
PH12013502305A1 (en) 2019-07-03
IL257475A (en) 2018-06-28
IL263728A (en) 2019-01-31
EA028574B1 (ru) 2017-12-29
US9555126B2 (en) 2017-01-31
JP6050328B2 (ja) 2016-12-21
BR112013029330A2 (pt) 2016-11-29
SG194894A1 (en) 2013-12-30
UA114401C2 (uk) 2017-06-12
MX2013013455A (es) 2014-02-17
BR112013029330A8 (pt) 2018-01-30
EP2710034A1 (en) 2014-03-26
EP2524929A1 (en) 2012-11-21
TW201834687A (zh) 2018-10-01
MY163736A (en) 2017-10-31
DOP2013000260A (es) 2014-01-31
AU2018201504A1 (en) 2018-03-22
JP2018021020A (ja) 2018-02-08
CN103547596A (zh) 2014-01-29
US20140072587A1 (en) 2014-03-13
JP6181273B2 (ja) 2017-08-16
CR20130593A (es) 2014-01-09
UY34077A (es) 2013-01-03
KR20140043388A (ko) 2014-04-09
AU2012258254A1 (en) 2013-05-02
GT201300276A (es) 2015-03-23
CN107007840A (zh) 2017-08-04
PH12017501368A1 (en) 2018-01-29
TN2013000468A1 (en) 2015-03-30
TW201726167A (zh) 2017-08-01
AU2016206317A1 (en) 2016-08-11
PE20141018A1 (es) 2014-08-27
AU2012258254B2 (en) 2016-04-21
JP2014515036A (ja) 2014-06-26

Similar Documents

Publication Publication Date Title
IL263728A (en) Use of an anti-19cd maytensinoid immunoconjugated antibody to treat symptoms of b-cell malignancy
SG11201401386XA (en) Treatment of hematologic malignancies with an anti-cxcr4 antibody
IL229582A0 (en) Antibodies against kir for the treatment of inflammatory disorders
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL228738A0 (en) Antibodies for cancer treatment
PL2665749T3 (pl) Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych
AP3544A (en) Compounds for the treatment of addiction
IL222198A0 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
ZA201401326B (en) Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer
PL2550296T3 (pl) Przeciwciała monoklonalne w leczeniu nowotworów
IL230693A0 (en) Use of the i-3859 antibody for the detection and diagnosis of cancer
EP2827902A4 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH ANTI-CD19 ANTIBODY
ZA201306807B (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
GB201121564D0 (en) Use of antibody
HK1190733A (en) Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
ZA201309332B (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer